Chandra Bhagat Pharma Ltd vs Medicamen Organics Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Chandra Bhagat Pharma Ltd is ₹ 31.6 as of 06 May 15:30 . The P/E Ratio of Chandra Bhagat Pharma Ltd is 0 as of March 2024 .The P/E Ratio of Medicamen Organics Ltd is 0 as of March 2024 . The Market Cap of Chandra Bhagat Pharma Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Medicamen Organics Ltd is ₹ 0 crore as of March 2024 . The Dividend Payout of Chandra Bhagat Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Medicamen Organics Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Chandra Bhagat Pharma Ltd

Chandra Bhagat Pharma Limited was incorporated as a Private Limited Company with the name 'Chandra Bhagat Pharma Private Limited' at Mumbai on March 10, 2003.
Consequent upon the conversion of the Company from Private Limited Company to Public Limited Company, the name of the Company was changed to 'Chandra Bhagat Pharma Limited' on March 20, 2019. The Company incorporated in March, 2003 by Mr. Hemant Bhagat and Late.
Shree Chandravadan Bhagat.
On April 1, 2003, the Company acquired the going concern business of M/s.
Chandra Bhagat Corporation, partnership firm along with all its assets and liabilities.

About Medicamen Organics Ltd

Medicamen Organics Limited was formerly incorporated on March 15, 1995 as Panchdeep Pharmaceuticals Limited', as Public Limited Company dated March 15, 1995 issued by the Registrar of Companies, Delhi and Haryana.
Subsequently, the name of Company changed to Medicamen Organics Limited' and a fresh Certificate of Incorporation on November 14, 1995 was issued by the Registrar of Companies, Delhi and Haryana at Delhi. Medicamen Organics are engaged in developing, manufacturing and distribution of broad range of pharmaceutical dosage including generic dosage in form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry Powders for Government (including both State and Central Governments) and Private Institutions as contract manufacturer / third party manufacturer.
The Company market product to private pharma companies in domestic as well as international markets through third party distributors or on loan license basis.

FAQs for the comparison of Chandra Bhagat Pharma Ltd and Medicamen Organics Ltd

Which company has a larger market capitalization, Chandra Bhagat Pharma Ltd or Medicamen Organics Ltd?

Market cap of Chandra Bhagat Pharma Ltd is 23 Cr while Market cap of Medicamen Organics Ltd is 34 Cr

What are the key factors driving the stock performance of Chandra Bhagat Pharma Ltd and Medicamen Organics Ltd?

The stock performance of Chandra Bhagat Pharma Ltd and Medicamen Organics Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Chandra Bhagat Pharma Ltd and Medicamen Organics Ltd?

As of May 6, 2026, the Chandra Bhagat Pharma Ltd stock price is INR ₹31.6. On the other hand, Medicamen Organics Ltd stock price is INR ₹29.2.

How do dividend payouts of Chandra Bhagat Pharma Ltd and Medicamen Organics Ltd compare?

To compare the dividend payouts of Chandra Bhagat Pharma Ltd and Medicamen Organics Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.